Ricevi le ultime notizie sulle azioni Nurix Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di NRIX

Ultime notizie per

NURIX THERAPEUTICS INC

Nurix Therapeutics

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Stuttgart,,Germany,-,03-11-2021:,Person,Holding,Cellphone,With,Company,Logo

Equities

News

Markets

ETFs

ADPT

ARKQ

NRIX

NVDA

PATH

Nuovi acquisti per il fondo guidato dalla celebre investitrice, focus su un settore chiave. Ribilanciamento in corso nel portafoglio.

Cathie Wood non si ferma più: Ark Invest compra ancora questi titoli

Nurix Therapeutics Inc

Press Releases

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

Health Care

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Earnings

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Absci

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma

Akebia Therapeutics

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

CareDx

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Erasca

Gyre Therapeutics

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

Keros Therapeutics

Kura Oncology

MeiraGTx Hldgs

Myriad Genetics

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Regenxbio

Rezolute

Tango Therapeutics

Tyra Biosciences

UroGen Pharma

Vir Biotechnology

Oppenheimer

Morgan Stanley

HC Wainwright & Co.

Stephens & Co.

Comments

Nurix Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO